欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2023, Vol. 28 ›› Issue (4): 400-406.doi: 10.12092/j.issn.1009-2501.2023.04.006

• 临床药理学 • 上一篇    下一篇

孕激素受体基因G1978T 多态性与子宫内膜癌的相关性研究

周晶1,3,周琛1,廖珂1,邱爱林1,董巍檑2,郭紫芬1   

  1. 1南华大学衡阳医学院药学院药物药理研究所,衡阳  421001,湖南;2南华大学附属第一医院妇产科,衡阳  421001,湖南;3邵阳学院附属第一医院药剂科,邵阳  422001,湖南
  • 收稿日期:2023-03-17 修回日期:2023-04-25 出版日期:2023-04-26 发布日期:2023-05-17
  • 通讯作者: 郭紫芬,女,博士,教授,研究方向:基因诊断与个体化用药。 E-mail:guozifen@aliyun.com
  • 作者简介:周晶,女,硕士,药师,研究方向:分子药理。 E-mail:949580741@qq.com
  • 基金资助:
    湖南省教育厅重点项目(19A419);邵阳学院附属第一医院科研项目(21FY1009)

Correlation between progesterone receptor G1978T polymorphism and endometrial cancer

ZHOU Jing1,3, ZHOU Chen1, LIAO Ke1, QIU Ailin1, DONG Weilei2, GUO Zifen1   

  1. 1Institute of Pharmacy and Pharmacology, School of Pharmaceutical Science, Hengyang Medical College, University of South China, Hengyang 421001, Hunan, China; 2Department of Obstetrics and Gynecology, the First Affiliated Hospital of University of South China, Hengyang 421001, Hunan, China; 3Department of Pharmacy, the First Affiliated Hospital of Shaoyang University, Shaoyang 422001, Hunan, China 
  • Received:2023-03-17 Revised:2023-04-25 Online:2023-04-26 Published:2023-05-17

摘要: 目的:探讨子宫内膜癌与孕激素受体(pro-gesterone receptor, PGR)基因G1978T 多态性的关联。方法:先在Pubmed、EMBASE、中国知网和万方数据库中检索子宫内膜癌患者孕激素受体G1978T基因分型的文献,提取数据用STATA15软件进行Meta分析,计算I2和OR(95%CI)。然后收集子宫内膜癌(EC组)和正常女性(对照组)的全血标本,参照Genebank数据库序列,设计PGR基因G1978T位点野生型G和突变型T序列的特异性检测引物,并硫化修饰其 3'末端,对采集样本进行高保真DNA 聚合酶介导的PCR反应,检测其基因型,并辅以测序验证。结果:多种遗传模型分析显示 PGR 基因G1978T 多态性与子宫内膜癌风险之间没有明显关联(等位基因模型OR=1.10,95%CI=0.98~1.24,P=0.072)。66例正常人全血DNA中检测出1例PGR基因G1978T突变,而在62例子宫内膜癌患者全血DNA中未检测出PGR基因G1978T突变。病例组和对照组两组之间基因型与等位基因频率的分布差异无统计学意义(P>0.05)。结论:PGR 基因G1978T 位点的多态性与子宫内膜癌的发生无关。

关键词: 子宫内膜癌, 孕激素受体, G1978T多态性

Abstract:

AIM: To explore the relationship between progesterone receptor (PGR) gene G1978T polymorphism and endometrial carcinoma. METHODS: After searching PubMed, EMBASE, Wan-fang and CNKI databases for literatures on PGR G1978T genotyping of endometrial cancer patients, the da- ta were extracted and odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using STATA15. The whole blood samples of endometrial carcinoma cases (EC group) and normal women (control group) were collected. Allelic-specific primers matching G1978T wild type G allele and mutant type T allele were designed with 3'terminal phos-phorothioate modification, and the two-directional primer extension was performed using Exo+polymerase to genotype PGR gene G1978T polymorphism and Sanger sequencing was used to  verify the genotype. RESULTS: PGR gene G1978T mutation was marginally associated with endometrial carcinoma risk (ORper allele =1.10,95%CI=0.98-1.24, P=0.072). At the same time, only 1 normal blood samples were found with PGR gene G1978T mutation, and the differences in genotypes and allele frequency between the case group and the control group were not statistically significant(P>0.05).CONCLUSION: The G1978T polymorphism of the PGR gene maybe not be associated with the risk of endometrial carcinoma.

Key words: endometrial carcinoma, progesterone receptor, G1978T polymorphism

中图分类号: